Here’s a bold statement: Despite widespread concerns, a groundbreaking review has found no clear evidence linking paracetamol use during pregnancy to autism or ADHD in children. But here’s where it gets controversial—this finding challenges claims made by high-profile figures, including former U.S. President Donald Trump, who suggested a causal link in 2025. So, what’s the real story?
In a rapid umbrella review published in the BMJ on November 10, 2025 (https://www.bmj.com/content/391/bmj-2025-088141), researchers analyzed nine comprehensive reviews encompassing 40 studies. Six of these studies focused on autism, while 17 examined ADHD. Collectively, they aimed to uncover whether paracetamol use during pregnancy could impact a child’s neurodevelopment. And this is the part most people miss—while some studies initially hinted at a possible connection, the review’s authors concluded that the evidence was far from conclusive.
The researchers noted that earlier reviews had suggested a “possible-to-strong association” between maternal paracetamol intake and neurodevelopmental disorders like autism or ADHD. However, after a meticulous analysis, they expressed “low to critically low confidence” in these findings. Why? Because seven out of the nine reviews cautioned against drawing causal conclusions, citing issues like insufficient data, biases in original studies, and unaccounted confounding factors.
Here’s the kicker: When the data were adjusted to account for familial factors—such as shared genetics, parental mental health, and socio-environmental influences—the apparent link between paracetamol exposure and autism or ADHD risk either vanished or significantly weakened. This suggests that family-related factors, rather than paracetamol itself, might explain the observed risks.
Boldly put, this raises a thought-provoking question: Are we blaming paracetamol for outcomes that may be rooted in genetics or family environment? The authors urge stakeholders—from regulatory bodies to pregnant women—to recognize the limitations of existing research. They emphasize that the lack of high-quality evidence on medication use during pregnancy remains a critical issue, stemming from historical underinvestment in women’s health research.
The review gained urgency after Trump’s comments in September 2025, which sparked public concern. In response, experts like Grainne McAlonan from King’s College London praised the review for its careful assessment, confirming that the evidence does not clearly link paracetamol use in pregnancy to autism or ADHD. Dimitrios Siassakos of University College London echoed this, noting that the studies claiming an association are often confounded by shared family factors.
Claire Anderson, president of the Royal Pharmaceutical Society, reassured expectant parents: “Paracetamol remains a safe and effective first-line treatment for pain or fever during pregnancy when taken as directed. If you have concerns, consult a pharmacist or healthcare professional.”
But here’s the lingering question: How should we interpret studies that suggest a link, even if it’s not causal? Does this open the door for further research into familial and environmental factors in neurodevelopmental disorders? We’d love to hear your thoughts in the comments—do you agree with the review’s conclusions, or do you think there’s more to the story?
